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Abstract
Background: To inform researchers about the methodology and results of epidemic estimation studies performed
for COVID-19 epidemic in Iran, we aimed to perform a rapid review.
Methods: We searched for and included published articles, preprint manuscripts and reports that estimated
numbers of cumulative or daily deaths or cases of COVID-19 in Iran. We found 131 studies and included 29 of
them.
Results: The included studies provided outputs for a total of 84 study-model/scenario combinations. Sixteen
studies used 3–4 compartmental disease models. At the end of month two of the epidemic (2020-04-19), the
lowest (and highest) values of predictions were 1,777 (388,951) for cumulative deaths, 20,588 (2,310,161) for
cumulative cases, and at the end of month four (2020-06-20), were 3,590 (1,819,392) for cumulative deaths, and 144,
305 (4,266,964) for cumulative cases. Highest estimates of cumulative deaths (and cases) for latest date available in
2020 were 418,834 on 2020-12-19 (and 41,475,792 on 2020-12-31). Model estimates predict an ominous course of
epidemic progress in Iran. Increase in percent population using masks from the current situation to 95% might
prevent 26,790 additional deaths (95% confidence interval 19,925–35,208) by the end of year 2020.
Conclusions: Meticulousness and degree of details reported for disease modeling and statistical methods used in
the included studies varied widely. Greater heterogeneity was observed regarding the results of predicted
outcomes. Consideration of minimum and preferred reporting items in epidemic estimation studies might better
inform future revisions of the available models and new models to be developed. Not accounting for under-
reporting drives the models’ results misleading.
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Background
“On 31 December 2019, the World Health Organization
(WHO) China Country Office was informed of cases of
pneumonia unknown etiology (unknown cause) detected
in Wuhan City, Hubei Province of China” [1]. The dis-
ease was officially designated as coronavirus disease
2019 or COVID-19 by WHO on 2020-02-11 [2]. Due to
the rapid outbreak of the disease worldwide, WHO
characterized the situation as a pandemic on 11 March
[3]. The first two confirmed cases of COVID-19 in Iran
were officially reported on 2020-02-19 in city of Qom,
by the Ministry of Health and Medical Education
(MOHME) (via [4, 5]). Since then, MOHME has offi-
cially reported number of cumulative and new con-
firmed cases, deaths, and recovered cases in a daily basis
on press conferences. Those numbers are available by
date on different web pages of the web site of the
MOHME but are not compiled in one page. To our best
knowledge, the most straightforward route to access cu-
mulative and daily deaths and cases is the compilation of
WHO situation reports or more comprehensive sources
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such as Johns Hopkins University dashboard for
COVID-19 [4, 5]. Web site of Iranian MOHME was
not accessible to us from Canada and United States
most of the time, with an “Access Forbidden” mas-
sage from the “Security Department” of MOHME at
several occasions.
Number of deaths and cases, in addition to other
characteristics of epidemic are very important in
decision-making and disease control. However, official
reports suffer from undercounting in all countries. A
relatively high percentage of patients with COVID-19
are asymptomatic or have a mild form of the disease
which increases the chance of remaining undiagnosed.
The emerging nature of COVID-19 has aggravated
undercounting, as many countries are not prepared
for conducting enough tests; as a result, many of sus-
pected cases or deaths may not ever be confirmed by
standard laboratory tests. Epidemiological studies of
COVID-19 and model-based predictions and estima-
tions are useful in assessing transmission rates, pre-
dicting epidemic trends and fatality rates with the
inclusion of different intervention, environmental (sea-
sonality), and virologic (mutations) scenarios, and
thus can help policymakers for informed decision
making in a timely way [6].
Despite the potential role of epidemic modeling and
estimation studies in predicting outbreak size and trend,
multiplicity of factors influencing viral disease transmis-
sion, relative uncertainty of data on model parameters,
shifting disease dynamics in the setting of evolving epi-
demic, and suboptimality of model building methods
and reporting, have been known to limit predictive
models’ usefulness. A systematic review of individual-
level prediction models for covid-19 concluded that
many of the models suffer from poor reporting, high risk
of bias, and optimistic reporting of performance [7].
Since the beginning of the outbreak in Iran, re-
searchers inside and outside the country have used
models to estimate or predict the size and trajectory of
the epidemic of COVID-19 in Iran. All of them are in-
troduced later in the methods and results section of this
article. Some of these studies have been published in sci-
entific journals, or available in their not yet peer-
reviewed form or are presented as official or unofficial
reports. We aimed to perform a rapid review mainly de-
scribing currently available COVID-19 estimates for
Iran. We did not intend to scrutinize or criticize the
studies or models at this point. Our objective was to re-
view methods and results of COVID-19 epidemic esti-
mation studies for Iran. The ultimate goal is to inform
the audience, policy makers and researchers, for better
decisions, as well as potential updates of their prediction
or estimation studies or new studies being designed and
conducted currently and in future.
Methods
Study design and outcomes of interest
This a rapid review, not a systematic review. The main
outcomes of interest were the predicted values (and cal-
endar dates) of (1) cumulative deaths, (2) cumulative
cases, (3) daily deaths, and (4) daily cases of COVID-19
in Iran. Deaths are less dependent on testing than cases.
Cumulative estimates do not show daily fluctuations.
Daily estimates help demonstrate epidemic waves and
peaks.
Place and time scope of target studies
We included all studies which their target population
was or included Iran, and we found them from 2020-03-
19 to 2020-04-12. We updated our search from 2020-
10-02 to 2020-10-05.
Search strategy and selection criteria
There is not a customized protocol for the items that
must be available in a report of epidemic estimation,
prediction or epidemic model. Carrasco et al. proposed a
‘CCPV’ protocol (Characteristics, Construction,
Parameterization and Validation aspects protocol) to
standardize the reporting of Influenza pandemic models
[8]. The items included in the “transparent reporting of
a multivariable prediction model for individual prognosis
or diagnosis” (TRIPOD) gives a general idea of the
reporting items, however it is not specifically for the rea-
son of epidemic prediction/ estimation models [9].
Wynants et al. review of prediction models for diagnosis
and prognosis of covid-19 infection, even though focus-
ing the individual-level modeling, can be considered in
reporting epidemic estimation studies [7].
Based on our understanding of the TRIPOD state-
ment, epidemic modelling literature, and the studies we
reviewed, we think an epidemic estimation / prediction
model is expected to report at least following items, that
we call them ‘preferred reporting items’: (1) Epidemic
start date and rationale, (2) Epidemic (disease) model
type and description, (3) Statistical model type, descrip-
tion, and equation(s), (4) Model assumptions and their
verification, (5) Model scenarios’ detailed description, (6)
Validation process and findings, (7) List and sources of
model parameters and input data, and (8) Model outputs
preferably with uncertainty intervals for scenarios. Some
of the reports that we found in our searching process
were not the final versions; we included any study if
met all the following ‘minimum reporting items’: (1)
Provided estimates for at least one of the COVID-19
four outcomes of interests (cumulative deaths, cumula-
tive cases, daily deaths or daily cases) in Iran in any
period of time, (2) Provided a list of input data and their
sources, (3) An explanation on methods of using input
data and generation of model outputs was available.
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Exclusion criteria were: (1) Absence of all four main
outcomes of interest, or (2) Absence of the minimum
reporting items, or (3) Elaboration on a previous model-
ing or estimation study without the aim (or content) of
updating or improving the previous estimates.
By “report”, we mean studies results of which were not
published as a journal article (or pre-print), but were re-
leased as short or long reports, available on the internet
or shared with researchers. There are differences be-
tween epidemic modeling, prediction, and estimation;
Modeling studies use explicit disease models and statis-
tical models. Prediction studies do not use explicit dis-
ease models but predict (project) the number of cases
and or deaths in future. Estimation studies provide esti-
mates of cases for a recent point in time. The common
feature of all these three study types is that they provide
estimates of cases and or deaths in at least one point in
calendar time. For pragmatic reasons, we call all of them
as estimation studies.
Study revisions / updates: We actively searched and
checked for revisions or updates of studies and their
published formats (from pre-print, to journal pre-proof,
to final published article). International studies update
their estimations on a periodical basis: (1) DELPHI
(Differential Equations Leads to Predictions of Hospitali-
zations and Infections) Epidemiological Case Predictions
(DELPHI) [10], (2) Youyang Gu (YYG) [11], (3) Institute
for Health Metrics and Evaluation (IHME) [12], (4)
Imperial College (Imperial) [13], (5) Los Alamos
National Laboratory (LANL) [14], and (6) Srivastava
[15]. We stopped using new estimate updates on 2020-
10-11, when we used the latest estimate by LANL (Los
Alamos National Laboratories) [14]. As such, the latest
estimation dates for international we finally included in
our review are as follows (references are for studies’ data
web sites): 2020-07-18 for DELPHI [16], 2020-10-05 for
Gu (YYG) [17], 2020-10-09 for IHME [18], 2020-10-06
for Imperial College [19], 2020-10-11 for LANL [20],
and 2020-09-12 for Srivastava [15]. We found a web site
[21] and a published article [22] by Sabri and colleagues.
We refer to them, as ‘Saberi (web site)’ and ‘Saberi (art-
icle)’ respectively. For the former, that included period-
ical updates, we used their 2020-03-30 version. Updates
to their previous model [21] were later discontinued.
We searched PubMed and used Google Scholar and
plain Google for articles (or reports) matching our study
inclusion criteria. The used keywords were Iran, COVID,
COVID-19, COVID 19, Corona, SARS-CoV-2, epidemic,
outbreak, pandemic, case*, death*, fatal*, mortalit*,
model*, estimat*, and predict*. The search syntax used
in PubMed is shown in the Appendix. We performed
the same search with keywords in Farsi in Google
Scholar, Google, Scientific Information Database (of
Iran) [23], and MAG-IRAN [24].
We also used studies or reports provided to us by our
researcher colleagues. We report all the found, included,
and excluded, studies using PRISMA 2009 flow diagram
(Moher et al. 2009) [25] in Appendix Figure 1.
Data abstraction methods
We developed a spreadsheet for abstracting the items of
methods and results from included studies – the items
not restricted to the minimum required ones. Each study
was reviewed independently by at least two authors, and
discrepancies were resolved with involvement of a third
reviewer. Two reviewers (MML and LJ) finalized the ab-
stracted items for methodology of the target studies.
For abstraction of the results of the studies, we se-
lected a set of six fixed calendar dates, and found and
recorded the estimated / predicted values of main out-
comes (cumulative deaths, cumulative cases, daily
deaths, or daily cases) for each of those dates. To start
with, we fixed the presumed epidemic start time on the
date on which the first two cases were officially reported
dead, on 2020-02-19 (1398-11-30 Hijri solar), although
later official reports indicated the actual start date of the
epidemic to be earlier. Rationale for this was that most
of the studies used the official reports to start with, and
most of the studies’ predictions also started from that
date (2020-02-19).
We decided not to include the estimations for the end
of the first, second and third weeks of the epidemic in
our set of fixed dates, since we were already in month
two of the epidemic, for sake of brevity, and considering
the less robust nature of the predictions as early as the
first month when the numbers were much smaller. The
set of six fixed calendar dates were designated as the end
of each Hijri solar month after the epidemic presumed
start date, since the start date coincided with the last day
of month 11 of the Hijri solar calendar, and as such, tar-
geting the end of each solar month would enhance
cross-study comparisons and further use of administra-
tive data. We did not report predictions beyond the
month six, for the sake of brevity, and given the more
uncertainty regarding such longer-term intervention sce-
narios and outcomes. However, we demonstrated all the
time span of the available predictions in our graphs to
provide a visual overview.
Most of the reviewed studies had considered more
than one scenario for the progression of the epidemic,
based on different intervention options, and we treated
them as study-scenarios. Some studies considered differ-
ent statistical models for prediction of epidemic pro-
gress, and we treated them as study-models. Altogether,
such arrangement provided multiple study-scenarios/
models for which we abstracted the estimated / pre-
dicted values of the main outcomes. Occasional studies
provided confidence limits for point estimates which
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were also recorded. Along with update of our search in
October 2020, we included estimated values for latest
dates available in 2020 (e.g. 2020-12-31) and in 2021
(e.g. 2021-01-31) where available.
Besides the six fixed dates, we also abstracted the data
for the following items for each study-scenario/model:
(a) predicted date of every peak in daily / new / active
cases or deaths, and (b) predicted date of ‘epidemic
control’ or equivalent (with the same study’s criteria or
definition of control). Predicted values of main outcomes
were recorded for these dates. We also recoded the
methods used for as assessment of each statistical
model’s validity (or fitness) and their findings.
Two reviewers (FP and MRH) abstracted the estimates
from the target studies. For abstraction of the main out-
comes’ values at the designated dates, we prioritized our
sources and methods as, (1) mention in article text and
tables, (2) digitization of article graphs. We used a web-
based plot digitizer, “WebPlotDigitizer 4.2” [26]. Our
error in digitizing data was less than 5%, as measured
using the following formula: error in digitizing = ((digi-
tized value – mentioned value) / (digitized value)), where
the mentioned value means the value that was men-
tioned in study text or tables. We used the reported
COVID-19 cases and deaths complied by the Johns
Hopkins University [4, 5] for each calendar date, as
equal to Iran’s official reported data compiled in WHO
situation reports. For developing our graphs, we chose
the median scenario/models for cumulative cases from
each study in order to demonstrate the main level of the
predictions in non-international studies. Only eight non-
international studies estimated cumulative deaths, so
that outcome could not be used for identification of me-
dian scenarios across all studies. In studies with even
number of scenario/models, we chose the one (of the
middle two) with the higher values of estimates. The
same selected median scenario/models for cumulative
cases were used to graph the outcomes where the pre-
dictions were available. We recorded the text, table
number, or the graph number for each study where we
extracted every single number or date used in our tables
and graphs. “Additional file 2 - Target studies’ abstracted
data” includes all the detailed data we abstracted from
the studies, as well as detailed findings from the studies’
methods.
Results
General characteristics of reviewed studies: We found
114 articles, 10 non-peer reviewed reports, and seven
web sites that described methods and present results of
estimations; a total of 131 results.
We included 18 published articles, two medRxiv pre-
prints, seven web sites of COVID-19 epidemic modeling
studies, and two non-peer-reviewed reports; a total of 29
studies. The two non-peer-reviewed reports were in
Farsi; Haghdoost [27], and Mashayekhi [28]. One pub-
lished article was in Farsi; Rahimi Rise [29]. Among the
seven included web sites, one estimated the outcomes in
Iran (Saberi [21]) and the six others were international
studies estimating the outcomes for multiple countries
on a periodical basis; DELPHI [10], Gu (YYG) [17],
IHME [12], Imperial College [13], LANL [14], and Sri-
vastava [15]. Three studies, DELPHI, Gu (YYG), and Los
Alamos did not have a publication, and whatever details
about their study methods are available on their study
web sites [10, 11, 14]. The three other international
studies have at least one publication each (as of 2020-
10-29): IHME, peer-review published [30], pre-print
[31–33]; Imperial College, peer-review published [34],
and Srivastava, pre-print [35]. For each of the six inter-
national studies, we mentioned the study web site, study
data site, and their publications. For reporting the num-
ber of the reviewed component studies, we count each
international study as one, rather than creating a hier-
archical clustered structure with study publication /
study web site at higher level and individual studies at
lower level. Appendix Figure 1 shows the PRISMA stud-
ies flow diagram.
We report our findings following the ‘preferred report-
ing items’ mentioned above.
Place: 19 studies included only Iran; the other 13 studies
included from 6 to 184 countries. Six studies included
subnational level estimates: Haghdoost [27], Moghadami
[36], Muniz-Rodriguez [37], Pourghasemi (PLoS ONE)
[38], Pourghasemi (IJID) [39], and Zhan [40].
Epidemic start date and rationale
Twenty studies mentioned the epidemic start date, nine of
which used presumed official start date of 2020-02-19.
Epidemic start date ranged from 2020-01-02 (Ghaffarza-
degan [41]) to 2020-02-20 (Moradi [42], Shen [43]).
Two studies (Moradi [42], Shen [43]) reported their
estimates starting from 2020 to 02-20 without mention
of the rationale. Ghaffarzadegan reported most of their
estimates starting from 2020-01-02, based on unofficial
reporting of suspected cases [41]. Haghdoost et al. desig-
nated their “Day-zero” as 2020-01-21 [Hijri solar date
1398-11-01], that is 20 days before the presumed official
epidemic start date of 2020-02-19 [27]. Many of the pre-
dicted outcome values are zero or close to zero in the
graphs prior to day 20 of the graphs. However, some of
the graphs do seem to show non-zero values for cases or
deaths before their day. They maintain that their start
date of the epidemic in Iran (2020-01-21) was designated
based on “available documentations and epidemiologic
analyses”. Mashayekhi et al. did not mention their epi-
demic start date, and prediction graphs’ time axis
showed day zero to 120 or 360 [28]. We made an
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assumption that their start date was 2020-02-19. Nine
studies did not mention the epidemic start date.
Epidemic (disease) model type and description
Sixteen studies used compartmental models: SEIR or
SEIR+ (nine studies), SIR or SIR+ (six studies), SLIR+
(one study). In model acronyms, ‘S’ stands for Suscep-
tible, ‘E’ for Exposed, ‘I’ for Infected, ‘R’ for Removed or
Recovered, and ‘L’ is for Latent. In any model with a +
sign, there are other components for augmentation of
model.
Statistical model type, description, and equation(s)
Some of the studies did not mentioned enough details
about their statistical methods and did not clearly differ-
entiate between the disease model and the statistical
model. Statistical methods used included growth models
(6 studies), dynamic models (4 studies), Auto-Regressive
Integrated Moving Average (ARIMA) (3 studies), regres-
sion models (3 studies), and ‘curve fitting and functional
analysis’, hyperparametric learning, machine learning,
minimization, smoothing model, and time series (each in
one study). Few studies provided formal representation
(equation) of the model.
Model assumptions and their verification
None of the reviewed studies did explicitly mention all
the assumptions, their verification methods, and results
of the verification. Most studies did report some details
about their assumptions.
Model scenarios’ detailed description
There were 77 study-scenarios (epidemic progression
scenarios) and 38 study-models (statistical models),
resulting in a total of 84 study-model/scenario combina-
tions. Fourteen studies used only one scenario (that
practically means no “scenario”). Fifteen other studies
used two to 12 scenarios (median 3). Nine studies in-
cluded policy intervention scenarios with different levels
of details mentioned. Eight studies used three levels of
interventions, that can be generally formulated as
‘current policies’, ‘more restrictions’, and ‘less restric-
tions’; Ahmadi [44], Ghaffarzadegan [41], Haghdoost
[27], IHME [12], Imperial [13], Mashayekhi [28], Saberi
(article) [22], Srivastava [15]. They varied substantially in
the level of details provided about what was meant by
more (or less) restrictions. Haghdoost also included a
baseline scenario of no interventions [27]. Imperial had
three additional ‘surged’ scenarios [13]. Mashayekhi and
IHME provided detailed-enough description of their
more (or less) restrictions [12, 28]. Policy interventions
or restrictions included physical social distancing in
Haghdoost [27], Mashayekhi [28], Rahimi Rise [29], and
IHME [12]. Haghdoost also used patient detection and
isolation [27]. Mashayekhi also included level of hygienic
precautions practiced by the general population [28].
Rahimi Rise also included alterations in preparations for
use of public transit [29]. IHME included use of masks
by the general population [12]. Two studies motioned
two levels of ‘no-policy’ and ‘actual policies’; Hsiang [45]
and Rahimi Rise [29]. Saberi (web site) [21] and Srivas-
tava [15] included under-reporting in official reports.
Ghaffarzadegan, Haghdoost, and IHME included season-
ality [12, 27, 41]. Tuite and Zhuang included air travel
data scenarios early in the epidemic [46, 47]. Ahmadi
started with statistical models and reasoned backwards
about what intervention scenarios could match each
statistical model [16, 44].
Ghaffarzadegan had two policy effect scenarios with
different levels of efforts to decrease contact rate as well
as three seasonality condition options, that amounted to
six total scenarios [41]. Haghdoost had four final scenar-
ios, each with levels of isolation for the infected and sus-
pected patients, as they maintained that “to postpone
the heavy wave of the disease, the most effective tool is
isolation of patients, in a way that the infected and sus-
pected patients would have the least contact with
healthy people”. In the early stages of model building,
they modeled “the effects of people’s behaviour change
and seasonality on disease transmission”, to show the
basic or worst model. Then three intervention scenarios
with different levels of isolations were added. The peo-
ple’s behaviour change and seasonality scenarios end
only in the basic or worst scenario with no intervention
[27]. Mashayekhi has three scenarios, each with different
levels of social [physical] contacts and observation of
sanitation cautions. As such, Mashayekhi and IHME
were the only studies that considered two modalities of
non-pharmacologic interventions [12, 28]. Details of
studies’ scenarios are presented in the Appendix.
There were factors other than deaths and / or cases,
one or more of which were considered in 11 studies.
Eight studies included policy interventions e.g. distan-
cing, quarantine, use of masks by general population;
DELPHI [10], Ghaffarzadegan [41], Haghdoost [27],
Hsiang [45], Imperial [13], Mashayekhi [28], Rahimi Rise
[29], and Thu [48]. Seven studies included asymptomatic
cases; DELPHI [10], Ghaffarzadegan [41], Gu (YYG)
[17], Mashayekhi [28], Saberi (article) [22], Rahimi Rise
[29], and Srivastava [15]. Six studies included under-
reporting and / or delays in reporting; DELPHI [10],
Ghaffarzadegan [41], Gu (YYG) [17], Saberi (web site)
[21], Saberi (article) [22], and Srivastava [15]. Three
studies included seasonality; Ghaffarzadegan [41], Hagh-
doost [27], and IHME [12]. Two studies included testing
availability and / or number of tests performed; Ghaffar-
zadegan [41] and IHME [12]. Two studies included en-
vironmental and meteorological variables; Pourghasemi
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(PLoS ONE) [38] and Pourghasemi (IJID) [39]. One
study included seroprevalence, as well as mobility in
population samples; IHME [12]. One study included co-
morbidities, as well as age stratification for mortality;
Imperial [13]. One study included changes to domestic
COVID-19-testing regimes, such as case definitions or
testing methodology; Hsiang [45]. The following items
were not incorporated in any of the scenarios of the in-
cluded studies: potential vaccine(s), potential pharmaco-
logical treatments, changes in cause of death definition,
possibility of reinfection, and possibility of mutations or
any change in virulence.
Validation process and findings
Eighteen studies provided one or more measures and re-
sults for model validation: Root Mean Squared Error
(RMSE) or Mean Squared Error (MSE) (9 studies), Mean
Absolute Percentage Error (MAPE) (4 studies), Mean
Absolute Error (MAE) (3 studies), Ratio Error (RE) (2
studies), R square (2 studies), Area Under Curve (AUC)
(2 studies), Akaike Information Criterion (AIC) (2 stud-
ies), and Root Mean Squared Relative Error (RMSRE) (1
study).
List and sources of model parameters and input data
Twenty-three studies used deaths and / or cases as input
data, source of which included MOHME official reports
(10 studies), Johns Hopkins University [4, 5] (6 studies),
source not mentioned (6 studies), and Worldometers
web site [49] (4 studies). Cases data were used in 23
studies and deaths data in 18 studies. Eleven studies
used additional input variables other than deaths and or
cases; eight studies used Non-Pharmaceutical Interven-
tion (NPI) variables and three studies used testing data.
List and sources of model parameters are available in
the Supplementary electronic material (“Studies’
Methods” tab). In Haghdoost’s study, for number of
deaths and cases to start with, assumptions were made
that on day-zero, there had been 1080 persons exposed
to the virus In Iran (including 75 in Tehran), from which
90 persons had become infected in Iran (including 5 in
Tehran) [27]. Four studies did not report using number
of confirmed cases or confirmed deaths as model input;
Tuite [46], Zhuang [47], Haghdoost [27], and Mashaye-
khi [28]. Among other studies, Ghaffarzadegan used
other sources of data, including unofficial reports for
number of cases and death and number of performed
tests [41].
Model outputs preferably with uncertainty intervals for
scenarios
Primary outcomes: The most frequent type of main out-
come was cumulative cases only (seven studies). Other
studies reported a combination of cumulative or daily
deaths or cases. Mashayekhi [28] reported estimates of
symptomatic and symptomatic cases separately, and
Saberi (article) [22] reported total number of confirmed
and suspected cases together. Thirteen studies provided
confidence intervals for the primary outcomes.
Forms of primary outcomes: The intended outcomes
and the terminology used in the included studies for the
same outcomes, varied across the studies. For daily
cases, two distinct groups could be recognized: daily in-
cident cases, and daily prevalent cases. Our designation
of daily incident cases included “new cases” reported
daily by MOHME (via [4, 5]), “new cases” predicted by
Haghdoost [27], and “daily cases” by Zareie [50]. Our
designation of daily prevalent cases included “current
cases” by Ghaffarzadegan [41], “maximum number of
cases per day” by Haghdoost [27], “daily cases” by
Mashayekhi [28], and “daily active cases” by Saberi (web
site) [21]. Active cases are the difference between total
cumulative cases with cumulative number of deceased
and recovered cases. Saberi (article) reported estimated
sum of daily confirmed and suspected cases [22].
Other outcomes: Four studies reported outcomes other
than deaths and / or cases. They reported different combi-
nations of hospitalization demand estimates (all beds, in-
tensive care unit beds, invasive ventilators); DELPHI [10],
Haghdoost [27], IHME [12], and Imperial [13].
Date range of estimates for deaths and / or cases: Start
dates of outputs ranged from 2019-12–31 (Ghaffarzade-
gan [41]) to 2020-09-19 (Srivastava [15]). End dates of
outputs ranged from 2020-02-24 (Zhuang [47]) to 2021-
02-02 (Saberi (web site) [21]). Outputs duration ranged
from 11 days (Muniz-Rodriguez [37]) to 364 days (IHME
[12]).
R0 estimation results: Eleven studies reported esti-
mated Reproductive Number values, ranging from 0.69
(95% CI 0.68–0.70) on 15 April 2020 (after control mea-
sures that took place) by Saberi (article) [22], to 7.24 at
the beginning of the epidemic by Haghdoost [27].
Twenty-one studies mentioned their study limitations,
among which 12 studies really described the limitations,
and the nine others touched the limitations very
minimally.
Increase in percent population using masks from the
current situation (i.e. current scenario) to 95% (i.e. best sce-
nario, 95% mask usage in public in every location) might
prevent 26,790 additional deaths (95% confidence interval
19,925–35,208) by the end of year 2020 (IHME [12]).
Table 1 summarizes the findings regarding the meth-
odology used in the reviewed studies. The six fixed
dates, the ends of months one to six, are used and
shown in Table 2. Table 2 shows the estimates of cumu-
lative deaths. Table 3 summarizes the outcomes at the
end of month two (2020-04-19) and month four (2020-
06-20) after the official epidemic start date, and the
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latest dates available in 2020 and 2021. Estimates of cu-
mulative cases, daily deaths and daily cases are demon-
strated in Appendix Tables 1, 2, and 3 respectively.
Appendix Table 4 demonstrates predictions of peak
dates and values of outcomes, and Appendix Table 5
shows predictions of epidemic control dates and values
of outcomes.
Figures 1, 2, and 3 demonstrate the reported and esti-
mated outcomes in median scenarios. Figures 1 and 2
show the cumulative deaths and cumulative cases re-
spectively. Figure 3 shows the daily deaths. In general,
international studies tend to replicate or imitate the offi-
cial national reports of deaths and cases up to the date
that they are available and estimate the future trajector-
ies for when the official reports seize to be available.
Therefore, adding such estimates from the international
studies does not provide added value. Hence, inter-
national studies’ estimates are not added to Figs. 1, 2
and 3. We created two graphs for the international stud-
ies’ estimates for Iran. The first one (Appendix Figure 8)
shows officially reported and “current scenario” esti-
mates of cumulative deaths for the whole time period
available, starting on 2020-01-03 (Imperial [13]) and
ending with 2021-02-01 (IHME [12]). The second
graph for the international studies’ estimates for Iran
is Fig. 4 and shows officially reported and “current
scenario” estimates of cumulative deaths for the last 4
months of 2020 and January 2021, as well as highest
and lowest estimates from other scenarios. Figure 5
shows the “current scenario” estimates of cumulative
deaths by IHME for Iran and 20 other countries in
North Africa Middle East region.
Appendix Figure 1 shows the PRISMA study flow dia-
gram. Appendix Figure 2 demonstrates the officially re-
ported cumulative confirmed cases, deaths, and
recovered cases, and Appendix Figure 3 shows the daily
equivalents. Appendix Figures 4 and 5 show the esti-
mated daily prevalent cases, with and without the esti-
mate form Saberi (web site) [21]. That estimate by
Saberi, even in the median scenario, had high values
compared to other studies. To visualize the quantitative
diversity of the studies’ results, we also graphed the re-
ported and worst-scenario estimated cumulative deaths
in Appendix Figures 6 and 7, with and without the esti-
mate form Mashayekhi [28]. That estimate by Mashaye-
khi, was the most extreme prediction among all the
studies. Appendix Figure 8 shows officially reported and
“current scenario” estimates of cumulative deaths by
international studies for Iran.
MOHME
Official reports of MOHME for cumulative deaths and
cases at 2020-10-19 were 30,712 and 534,631 respect-
ively (via [4, 5]). Peaks in daily deaths (and dates) were
158 (2020-04-04), 235 (2020-07-28), and 337 (2020-10-
19). Peaks in daily cases (and dates) were 3,186 (2020-
03-30), 3,574 (2020-06-04), and 6,191 (2020-10-25).
Cumulative deaths
Lowest and highest predicted cumulative deaths for the
end of the second month (2020-04-19) were 1777 (Im-
perial [13]) and 388,951 (Rafieenasab [54]) respectively,
when the official number was 5,118. At the end of
month four (2020-06-20), they were 3,590 (Imperial
[13]) and 1,819,392 (Mashayekhi [28]), and the official
number was 9,507. Those estimates for latest date
available in 2020 were 16,176 (Imperial [13] for 2020-
12-31) and 418,834 (Srivastava [15], for 2020-12-19).
For the latest date available in 2021, those estimates
were 40,151 (IHME [12], for 2021-01-31) and 125,690
(IHME [12], for 2021-01-31).
Cumulative cases
Lowest and highest predicted cumulative cases for the
end of the second month (2020-04-19) were 20,588 (Al-
Qaness [51]) and 2,310,161 (IHME [12]) respectively.
Where the official number was 82,211. At the end of
month four (2020-06-20), those estimates were 144,305
(DELPHI [10]) and 4,266,964 (IHME [12]), and the offi-
cial number was 202,584. Those estimates for latest date
available in 2020 were 3,588,293 (Imperial [13], for
2020-12-31) and 41,475,792 (Imperial [13], for 2020-12-
31). For the latest date available in 2021, those estimates
were 19,799,934 (IHME [12], for 2021-01-31) and 34,
417,912 (IHME [12], for 2021-01-31).
Daily deaths
Lowest and highest predicted daily deaths for the end of
the second month (2020-04-19) were 30 (Imperial [13])
and 11,289 (Rahimi Rise [29]) respectively, where the of-
ficial number was 87. At the end of month four (2020-
06-20), they were 5 (Mashayekhi [28]) and 44,934
(Mashayekhi [28]), and the official number was 115.
Those estimates for latest date available in 2020 were
zero (Imperial [13], for 2020-12-31) and 3,984 (Imperial
[13], for 2020-12-31). For the latest date available in
2021, those estimates were 55 (IHME [12], for 2021-01-
31) and 1,093 (IHME [12], for 2021-01-31).
Daily cases
Lowest and highest predicted daily incident cases for the
end of the second month (2020-04-19) were 93 (Thu
[48]) and 216,262 (Rahimi Rise [29]) respectively, where
the official number was 1,343. At the end of month four
(2020-06-20), they were 211 (DELPHI [10]) and 138,892
(Gu (YYG) [11]), and the official number was 2,322.
Those estimates for latest date available in 2020 were
zero (Imperial [13], for 2020-12-31) and 486,745
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Table 2 Predictions of cumulative deaths for the end of months one to six after the official epidemic start date (2020-02-19) and
the latest date available in 202
Date1a 20-03-19 20-04-19 20-05-20 20-06-20 20-07-21 20-08-21 Latest date
Date 2 b 98-12-29 99-01-31 99-02-31 99-03-31 99-04-31 99-05-31 in 2020 c
- First Author, Outcome S/M d Value Value Value Value Value Value Value
- MOHME official via ([4, 5])
Cumulative deaths N/A e 1,284 5,118 7,183 9,507 14,634 20,376 30,712
- Ahmadi [44]
Cumulative deaths M1 f 1,264 ·· ·· ·· ·· ·· ··
Cumulative deaths M2 g 1,322 ·· ·· ·· ·· ·· ··
Cumulative deaths M3 h 1,263 ·· ·· ·· ·· ·· ··
- DELPHI [10]
Total detected deaths S1i ·· ·· ·· 8,426 ·· ·· ··
- Ghaffarzadegan [41]
Cumulative deaths S1P1 j 15,317 44,078 70,462 95,658 ·· ·· ··
Cumulative deaths S1P2 k 15,317 41,702 52,937 66,549 ·· ·· ··
Cumulative deaths S2P1 l 15,317 44,078 68,383 85,262 ·· ·· ··
Cumulative deaths S2P2 m 15,317 41,702 52,937 60,015 ·· ·· ··
Cumulative deaths S3P1 n 15,317 44,078 68,383 80,213 ·· ·· ··
Cumulative deaths S3P2 o 15,317 41,702 52,937 57,341 ·· ·· ··
- Gu (YYG) [17]
Cumulative deaths, mean S1i ·· ·· ·· ·· ·· 31,955 ··
Cumulative deaths, lower S1i ·· ·· ·· ·· ·· 29,231 ··
Cumulative deaths, upper S1i ·· ·· ·· ·· ·· 36,014 ··
- Haghdoost [27]
Cumulative deaths S0 p ·· ·· 30,700 ·· ·· ·· ··
Cumulative deaths S1 q 3,824 9,107 13,450 ·· ·· ·· ··
Cumulative deaths S2 r 2,796 6,231 8,632 ·· ·· ·· ··
Cumulative deaths S3 s ·· ·· 6,030 ·· ·· ·· ··
- IHME [12]
Cumulative deaths, mean t S1 u 1,215 5,150 7,183 9,495 14,642 20,369 44,087
Cumulative deaths, lower t S1 u 1,215 5,150 7,183 9,495 14,642 20,369 38,031
Cumulative deaths, upper t S1 u 1,215 5,150 7,183 9,495 14,642 20,369 51,027
Cumulative deaths, mean t S2 v 1,215 5,150 7,183 9,495 14,642 20,369 67,186
Cumulative deaths, lower t S2 v 1,215 5,150 7,183 9,495 14,642 20,369 57,913
Cumulative deaths, upper t S2 v 1,215 5,150 7,183 9,495 14,642 20,369 72,170
Cumulative deaths, mean t S3 w 1,215 5,150 7,183 9,495 14,642 20,369 70,877
Cumulative deaths, lower t S3 w 1,215 5,150 7,183 9,495 14,642 20,369 57,956
Cumulative deaths, upper t S3 w 1,215 5,150 7,183 9,495 14,642 20,369 86,235
- Imperial [13]
Cumulative deaths, mean S1 x 763 3,743 5,276 7,303 11,537 16,538 27,195
Cumulative deaths, lower S1 x 434 2,095 3,067 4,203 6,537 9,895 17,638
Cumulative deaths, upper S1 x 1,254 6,096 8,462 11,620 17,058 23,543 36,103
Cumulative deaths, mean S2 y 763 3,743 5,276 7,303 11,537 16,538 32,372
Cumulative deaths, lower S2 y 434 2,095 3,067 4,203 6,537 9,895 19,989
Cumulative deaths, upper S2 y 1,254 6,096 8,462 11,620 17,058 23,543 45,124
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Table 2 Predictions of cumulative deaths for the end of months one to six after the official epidemic start date (2020-02-19) and
the latest date available in 202 (Continued)
Date1a 20-03-19 20-04-19 20-05-20 20-06-20 20-07-21 20-08-21 Latest date
Date 2 b 98-12-29 99-01-31 99-02-31 99-03-31 99-04-31 99-05-31 in 2020 c
Cumulative deaths, mean S3 z 763 3,743 5,276 7,303 11,537 16,538 121,960
Cumulative deaths, lower S3 z 434 2,095 3,067 4,203 6,537 9,895 42,697
Cumulative deaths, upper S3 z 1,254 6,096 8,462 11,620 17,058 23,543 252,429
Cumulative deaths, mean S4 aa 744 3,616 5,089 7,053 11,102 15,908 26,738
Cumulative deaths, lower S4 aa 388 1,777 2,572 3,590 5,960 9,019 16,176
Cumulative deaths, upper S4 aa 1,127 5,712 8,112 10,778 16,171 22,470 35,621
Cumulative deaths, mean S5 bb 744 3,616 5,089 7,053 11,102 15,908 31,916
Cumulative deaths, lower S5 bb 388 1,777 2,572 3,590 5,960 9,019 18,504
Cumulative deaths, upper S5 bb 1,127 5,712 8,112 10,778 16,171 22,470 48,300
Cumulative deaths, mean S6 cc 744 3,616 5,089 7,053 11,102 15,908 85,087
Cumulative deaths, lower S6 cc 388 1,777 2,572 3,590 5,960 9,019 40,819
Cumulative deaths, upper S6 cc 1,127 5,712 8,112 10,778 16,171 22,470 158,299
- LANL [14]
Cumulative deaths, median S1i 1,284 5,118 7,183 9,507 14,634 20,376 34,263
Cumulative deaths, lower S1i 1,284 5,118 7,183 9,507 14,634 20,376 30,762
Cumulative deaths, upper S1i 1,284 5,118 7,183 9,507 14,634 20,376 43,022
- Mashayekhi [28]
Cumulative deaths S1 dd 759 10,316 11,751 11,857 ·· ·· ··
Cumulative deaths S2 ee 1,285 33,349 61,322 77,302 86,931 92,620 ··
Cumulative deaths S3 ff 11,752 97,445 612,953 1,819,392 3,002,721 3,562,136 ··
- Moghadami [36]
Cumulative deaths, meangg S1i 1,144 5,378 ·· ·· ·· ·· ··
Cumulative deaths, lowergg S1i 1,104 3,929 ·· ·· ·· ·· ··
Cumulative deaths, uppergg S1i 1,166 7,003 ·· ·· ·· ·· ··
- Rafieenasab [54]
Cumulative deaths S2 hh 32,101 39,026 ·· ·· ·· ·· ··
Cumulative deaths S3 ii 69,583 388,951 402,569 ·· ·· ·· ··
- Srivastava [15]
Cumulative deaths S1P1 jj ·· ·· ·· ·· ·· ·· 43,631
Cumulative deaths S1P2 kk ·· ·· ·· ·· ·· ·· 43,282
Cumulative deaths S1P5 ll ·· ·· ·· ·· ·· ·· 42,289
Cumulative deaths S1P10 mm ·· ·· ·· ·· ·· ·· 40,802
Cumulative deaths S1P20 nn ·· ·· ·· ·· ·· ·· 38,324
Cumulative deaths S1P40 oo ·· ·· ·· ·· ·· ·· 34,721
Cumulative deaths S2P1 pp ·· ·· ·· ·· ·· ·· 418,834
Cumulative deaths S2P2 qq ·· ·· ·· ·· ·· ·· 354,756
Cumulative deaths S2P5 rr ·· ·· ·· ·· ·· ·· 241,214
Cumulative deaths S2P10 ss ·· ·· ·· ·· ·· ·· 154,826
Cumulative deaths S2P20 tt ·· ·· ·· ·· ·· ·· 87,664
Cumulative deaths S2P40 uu ·· ·· ·· ·· ·· ·· 45,995
Cumulative deaths S3P1 vv ·· ·· ·· ·· ·· ·· 27,959
Cumulative deaths S3P2 ww ·· ·· ·· ·· ·· ·· 27,786
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Table 2 Predictions of cumulative deaths for the end of months one to six after the official epidemic start date (2020-02-19) and
the latest date available in 202 (Continued)
Date1a 20-03-19 20-04-19 20-05-20 20-06-20 20-07-21 20-08-21 Latest date
Date 2 b 98-12-29 99-01-31 99-02-31 99-03-31 99-04-31 99-05-31 in 2020 c
Cumulative deaths S3P5 xx ·· ·· ·· ·· ·· ·· 27,327
Cumulative deaths S3P10 yy ·· ·· ·· ·· ·· ·· 26,724
Cumulative deaths S3P20 zz ·· ·· ·· ·· ·· ·· 25,909
Cumulative deaths S3P40 aaa ·· ·· ·· ·· ·· ·· 25,043
a Date 1: Gregorian
b Date 2: Hijri
c Latest date in 2020: As of 2020-10-19 for MOHME official via ([4, 5]), 2020-11-01 for Gu (YYG) [17], 2020–12–31 for IHME [12] and Imperial [13] [2020-11-28 for
LANL [14], and 2020-12-19 for Srivastava [15]
d S/M: Scenario / Model
e N/A: Not Applicable
f M1: Gompertz
g M2: Von Bertalanffy growth
h M3: Cubic Polynomial
i S1: Single scenario
j S1P1: Seasonality conditions 1 (no effect or status quo) and Policy effect 1 (status quo contact rate). Estimates for 2020-03-19, the end of first month after the
epidemic start date, are equal across the six scenarios
k S1P2: Seasonality conditions 1 (no effect or status quo) and Policy effect 2 (aggressive efforts to decrease contact rate by half of what it would be otherwise)
l S2P1: Seasonality conditions 2 (moderate effect; infectivity of the virus decreases linearly from April 1st and halves by June 1st, then stays the same for the rest
of the simulation) and Policy effect 1 (status quo contact rate)
m S2P2: Seasonality conditions 2 (moderate effect; infectivity of the virus decreases linearly from April 1st and halves by June 1st, then stays the same for the rest
of the simulation) and Policy effect 2 (aggressive efforts to decrease contact rate by half of what it would be otherwise)
n S3P1: Seasonality conditions 3 (very strong mitigating effect; infectivity of the virus decreases from April 1st to a quarter of its base value by June 1st, then stays
the same for the rest of the simulation) and Policy effect 1 (status quo contact rate)
o S3P2: Seasonality conditions 3 (very strong mitigating effect; infectivity of the virus decreases from April 1st to a quarter of its base value by June 1st, then stays
the same for the rest of the simulation) and Policy effect 2 (aggressive efforts to decrease contact rate by half of what it would be otherwise)
p S0: Basic scenario (no intervention), only 10% isolation
q S1: Worst scenario, minimum (25%) isolation
r S2: Medium scenario, medium (32%) isolation
s S3: Best scenario, maximum (40%) isolation
t Smoothed estimates
u S1 Best (Masks): ‘Universal Masks’ scenario reflects 95% mask usage in public in every location
v S2 Reference (Current): ‘Current projection’ scenario assumes social distancing mandates are re-imposed for 6 weeks whenever daily deaths reach 8 per million
(0.8 per 100,000)
w S3 Worse (Easing): ‘Mandates easing’ scenario reflects continued easing of social distancing mandates, and mandates are not re-imposed
x S1: Additional 50% Reduction
y S2: Maintain Status Quo
z S3: Relax Interventions 50%
aa S4: Surged Additional 50% Reduction
bb S5: Surged Maintain Status Quo
cc S6: Surged Relax Interventions 50%
dd S1: Serious distancing
ee S2: Not serious distancing
ff S3: Worse than Scenario 2
gg Dates for Moghadami [36] are 2020-03-21 and 2020-04-18, instead of 2020-03-19 and 2020-04-19 respectively
hh S2: Based on SIR model
ii S3: Approximation calculation
jj S1P1: Scenario Current, Parameter 1
kk S1P2: Scenario Current, Parameter 2
ll S1P5: Scenario Current, Parameter 5
mm S1P10: Scenario Current, Parameter 10
nn S1P20: Scenario Current, Parameter 20
oo S1P40: Scenario Current, Parameter 40
pp S2P1: Scenario Released, Parameter 1
qq S2P2: Scenario Released, Parameter 2
rr S2P5: Scenario Released, Parameter 5
ss S2P10: Scenario Released, Parameter 10
tt S2P20: Scenario Released, Parameter 20
uu S2P40: Scenario Released, Parameter 40
vv S3P1: Scenario Restricted, Parameter 1
ww S3P2: Scenario Restricted, Parameter 2
xx S3P5: Scenario Restricted, Parameter 5
yy S3P10: Scenario Restricted, Parameter 10
zz S3P20: Scenario Restricted, Parameter 20
aaa S3P40: Scenario Restricted, Parameter 40
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(Imperial [13], for 2020-12-31). For the latest date avail-
able in 2021, those estimates were 14,818 (IHME [12], for
2021-01-31) and 236,781 (IHME [12], for 2021-01-31).
Lowest and highest predicted daily incident confirmed
and suspected cases for the end of the second month
(2020-04-19) were 72,950 (Saberi (article) [22]) and 1,616,
385 (Saberi (article) [22]) respectively; there are no
correspondent official numbers for this measure. At the
end of month four (2020-06-20), they were 9,625 (Saberi
(article) [22]) and 1,255,012 (Saberi (article) [22]).
Peak dates and control dates
In general, studies with shorter (or longer) durations of
outputs estimated lower (or higher) numbers of peaks.
Table 3 Lowest and highest predictions at the end of month 2 (2020-04-19), month 4 (2020-06-20) after the official epidemic start
date (2020-02-19), and the latest dates available in 2020 and 2021
Outcomes: Lowest Study MOHME Highest Study
- End of month 2 (20–04-19)
Cumulative deaths 1,777 Imperial a 5,118 388,951 Rafieenasab b
Daily deaths 30 Imperial a 87 11,289 Rahimi Rise c
Cumulative cases 20,588 Al-Qaness d 82,211 2,310,161 IHME e
Incident daily cases 93 Thu f 1,343 216,262 Rahimi Rise c
Incident daily total cases g k 72,950 Saberi (paper) h .. 1,616,385 Saberi (paper) i
- End of month 4 (20–06-20)
Cumulative deaths 3,590 Imperial a 9,507 1,819,392 Mashayekhi j
Daily deaths 5 Mashayekhi k 115 44,934 Mashayekhi j
Cumulative cases 144,305 DELPHI l 202,584 4,266,964 IHME e
Incident daily cases 211 DELPHI l 2,322 138,892 Gu (YYG) m
Incident daily total cases g 9,625 Saberi (paper) h .. 1,255,012 Saberi (paper) i
- Latest date available in 2020
Cumulative deaths 16,176 Imperial n 30,712 o 418,834 Srivastava p
Daily deaths 0 Imperial a 373 o 3,984 Imperial q
Cumulative cases 3,588,293 Imperial n 534,631o 41,475,792 Imperial q
Incident daily cases 0 Imperial a 4,251o 486,745 Imperial e
Incident daily total cases g 9,625 Saberi (paper) h .. 169,110 Saberi (paper) i
- Latest date available in 2021
Cumulative deaths 40,151 IHME r .. 125,690 IHME s
Daily deaths 55 IHME r .. 1,093 IHME s
Cumulative cases 19,799,934 IHME r .. 34,417,912 IHME s
Incident daily cases 14,818 IHME r .. 236,781 IHME s
a Imperial, S4: Surged Additional 50% Reduction. Lower 95% uncertainty limit [13]
b Rafieenasab, S3: Approximation calculation. Mean estimate [54]
c Rahimi Rise, S2: No interventions. Mean estimate [29]
d Al-Qaness, M1: Adaptive Neuro-Fuzzy Inference System (ANFIS) enhanced with Genetic Algorithm (GA). Mean estimate [51]
e IHME, S2 Reference (Current): ‘Current projection’ scenario assumes social distancing mandates are re-imposed for 6 weeks whenever daily deaths reach 8 per
million (0.8 per 100,000). Upper 95% uncertainty limit [12]
f Thu, M1: Linear growth rate, eq. 1. Mean estimate [48]
g Saberi (paper), Incident daily total cases (confirmed and suspected) [22]
h Saberi (paper), S1: 20% more distancing. Mean estimate [22]
i Saberi (paper), S3: 20% less distancing. Upper 95% uncertainty limit [22]
j Mashayekhi, S3: Worse than Scenario 2 (S2: Not serious distancing). Mean estimate [28]
k Mashayekhi, S1: S1: Serious distancing. Mean estimate [28]
l DELPHI, S1: Single scenario. Mean estimate [10]
m Gu (YYG) S1, Single scenario. Upper 95% uncertainty limit [17]
n Imperial, S4: Surged Additional 50% Reduction. Lower 95% uncertainty limit. For 2020-12-31 [13]
o MOHME official via ([4, 5]), as of 2020-10-19
p Srivastava, S2P1: Scenario Released, Parameter 1. mean estimate For 2020-12-19 [15]
q Imperial, S3: Relax Interventions 50%. Upper 95% uncertainty limit. For 2020-12-31 [13]
r IHME, S1Best (Masks): ‘Universal Masks’ scenario reflects 95% mask usage in public in every location. Lower 95% uncertainty limit. For 2021-01-31 [12]
s IHME, S3 Worse (Easing): ‘Mandates easing’ scenario reflects continued easing of social distancing mandates, and mandates are not re-imposed. Upper 95%
uncertainty limit. For 2021-01-31 [12]
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For daily deaths, official reports showed the first peak of
158 (2020-04-04), second peak of 235 (2020-07-28), and
third peak of 337 (2020-10-19). For estimates of daily
deaths, size (and date) of the lowest first peak was 81
(2020-06-01) (LANL [14]), and the highest first peak was
44,934 (2020-06-20) (Mashayekhi [28]). For the third
peak, lowest estimate was 134 (2020-09-29) (Imperial
[13]) and highest estimate was 4,968 (2020-12-11) (Im-
perial [13]). For daily cases, official reports showed the
first peak of 3,186 (2020-03-30), second peak of 3,574
(2020-06-04), and third peak of 4,830 (2020-10-14). For
estimates of daily cases, size (and date) of the lowest first
peak was 1,050 (2020-03-12) (Shen [43]), and the highest
first peak was 470,229 (2020-03-31) (Rahimi Rise [29]).
For the second peak, lowest estimate was 3,825 (2020-10-
010) (LANL [14]) and highest estimate was 14,272 (2020-
03-11) (Haghdoost [27]). For the third peak, lowest
estimate was 6,526 (2020-10-25) (LANL [14]) and highest
estimate was 717,356 (2020-12-04) (Imperial [13]).
Three studies predicted the epidemic control (or end)
dates and outcome’s values. Two studies predicted the
potential date for epidemic to be controlled in April;
Ahmadi et al. predicted the “end of the epidemic” on
2020-05-13 with 87,000 cumulative cases or on 2020-06-
01 with 4,900 cumulative deaths (using Von Bertalanffy
model) or 11,000 cumulative deaths (using Gompertz
model) [44]. Haghdoost predicted that with their either
medium or best scenarios, the epidemic would be well
controlled in month 2 of Hijri solar year 1,399 (2020-04-
20 to 2020-05-20). Their ‘maximum number of infected
people in day’ would be 92,100 in middle scenario and
9150 in best scenario [27]. Zhan et al. predicted that if
the “authorities continue to impose strict control mea-
sures, the epidemic will come under control by the end
of April and is expected to end before June 2020, and as
the quality of treatment improves, more rapid recovery
will be expected” [40]. Beyond the correspondent values
of the predicted outcomes, no further criteria or defin-
ition of epidemic end or control was provided.
Discussion
There were lots of heterogeneity in methods and find-
ings of the COVID-19 prediction models and estimation
studies for Iran. After the presumed official start date of
the COVID-19 epidemic in Iran, i.e. 2020-02-19, and at
the end of month two (2020-04-19), the lowest (and
highest) values of predictions were 1777 (388,951) for
cumulative deaths, 20,588 (2,310,161) for cumulative
cases, and at the end of month four (2020-06-20), they
were 3,590 (1,819,392) for cumulative deaths, and 144,
Fig. 1 Reported and median-scenario estimated cumulative deaths of COVID-19 in Iran . (1) Ahmadi M2: Model 2, Von Bertalanffy (Curve lies
behind MOHME reported) [44]. (2) Ghaffarzadegan S1P1: Seasonality conditions 1 (no effect or status quo) and Policy effect 2 (aggressive efforts
to decrease contact rate by half of what it would be otherwise) [41]. (3) Haghdoost S2: Medium scenario, medium (32%) isolation (Curve lies
behind MOHME reported) [27]. (4) Mashayekhi S2: Medium scenario, not serious distancing; People reduce their social [physical] contacts only to
20% of regular level, voluntarily, after number of cases and deaths have increased, and other settings are like scenario one [28]. (5) Deaths CF 5:
Reported deaths with a Correction Factor of 5, after Dr. Rick Brennan, Director of Emergency Operations, World Health Organization [57]. (6)
Deaths CF 10: Reported deaths with a Correction Factor of 10, after Russell [58]. (7) MOHME reported: Official reported deaths via [4, 5]
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305 (4,266,964) for cumulative cases. Lowest and highest
predicted cumulative deaths for latest date available in
2020 were 16,176 (Imperial [13], for 2020-12-31) and 418,
834 (Srivastava [15], for 2020-12-19). For the latest date
available in 2021, those estimates were 40,151 (IHME
[12], for 2021-01-31) and 125,690 (IHME [12], for 2021-
01-31). Lowest and highest predicted cumulative cases for
latest date available in 2020 were 3,588,293 (Imperial [13],
for 2020-12-31) and 41,475,792 (Imperial [13], for 2020-
12-31). For the latest date available in 2021, those esti-
mates were 19,799,934 (IHME [12], for 2021-01-31) and
34,417,912 (IHME [12], for 2021-01-31).
Part of the heterogeneity observed in component stud-
ies’ methods originates from the actual lack of universal
consensus-based standards for epidemic modeling study
methodology and reporting. Another part originates
from studies’ adherence to principles of reporting their
methods and findings. For instance, eight of the
reviewed studies did not mention their study limitations
at all, and nine studies did mention limitations but just
touched the limitations very minimally.
Part of the heterogeneity observed in studies’ findings
originates from choices of methods and assumptions, in-
cluding the untrue assumptions of homogeneous popu-
lation mixing, no role of asymptomatic cases in disease
spread, and no under-reporting of deaths and cases. An-
other part originates from quality, availability, and com-
pleteness of data, including, epidemic start date, and
numbers of cases and deaths.
The epidemic start date and the reported number
of deaths and cases are the most important starting
points for epidemic estimation studies. There are un-
certainties about the epidemic start date and real
numbers of deaths and cases. The presumed official
start date of the COVID-19 epidemic in Iran was
2020-02-19, when the first two tandem cases were re-
ported as dead. Report of the first case or cases as
dead on the same date they were diagnosed is not the
most frequent type of reporting in this pandemic.
Haghdoost et al. study, dated 2020-03-15 [1,398-12-25
Hijri solar], maintains that their start date of the epi-
demic in Iran for their modeling purpose was desig-
nated as 2020-01-21 [1,398-11-01 Hijri solar] based
on “available documentations and epidemiologic ana-
lyses” [27]. No description or references were pro-
vided for their “available documentations and
epidemiologic analyses”. Two days later, MOHME an-
nounced in 2020-03-27 that the epidemic had prob-
ably started in month 11 of Hijri solar year 1,398
(2020-01-21 to 2020-02-19) [59]. As such, the models
Fig. 2 Reported and median-scenario estimated cumulative case of COVID-19 in Iran. (1) Ahmadi M2: Model 2, Von Bertalanffy (Curve lies behind
MOHME reported) [44]. (2) Ghaffarzadegan S1P1: Seasonality conditions 1 (no effect or status quo) and Policy effect 2 (aggressive efforts to
decrease contact rate by half of what it would be otherwise) [41]. (3) Haghdoost S2: Medium scenario, medium (32%) isolation [27]. (4) Moradi S2:
Scenario 2, Case Fatality Rate, 0.5% [42]. (5) Cases CF 5: Reported cases with a Correction Factor of 5, after Dr. Rick Brennan, Director of Emergency
Operations, World Health Organization [57]. (6) Cases CF 10: Reported cases with a Correction Factor of 10, after Russell [58]. (7) MOHME reported:
Official reported cases via [4, 5]
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that use the official start date of 2020-02-19 start
with an inaccurate start date of the epidemic to begin
with.
WHO Country Support Mission to Iran (2–11 March
2020) reported the following: “On 20 February, the Is-
lamic Republic of Iran IHR [International Health Regula-
tions] National Focal Point (IHR-NFP) notified WHO of
five cases, including two deaths, of laboratory-confirmed
COVID-19 cases. Three of the cases were from Qom
City, and the fourth had a travel history to Qom. In the
following days, the investigation concluded that the virus
was probably circulating in Qom for several weeks,
based on the following observations: Among 186 pa-
tients with severe acute severe acute respiratory infec-
tion (SARI) hospitalized during February, 8 deaths were
observed (0 deaths for the same month last year). Sam-
ples taken in February in patients with influenza-like ill-
ness (ILi) symptoms that tested negative for Influenza
were also tested for COVID-19. Among workers of the
Salafchegan free zone located 50 km from Qom city
centre, 5 tests were positive for COVID-19; their onset
of symptoms was 10 February. In late February, of 17
Chinese workers who had not traveled back to China for
the Chinese New Year, 5 tested positive.” [57]. As such,
most of the models start with an inaccurate start date of
the epidemic to begin with, and most of the studies rely
on the officially reported numbers of cases and deaths.
Iran’s MOHME stopped reporting provincial cases and
deaths on 2020-03-23 [45].
In addition to Ghaffarzadegan [41] that used both
official and unofficial data as input, one study (Saberi
[21]), also used correction factors of 5 and 10 taken
from other sources [57] or studies [58] applied to the
officially reported numbers of cases and deaths. A
correction factor of 20 has been proposed for the epi-
demic in Iran [60]. We do not know when or where
were the results of the ‘investigation’ referred to in
the above quoted “In the following days, the investi-
gation concluded that …” , were announced or pub-
lished. The first COVID-19 patient “with a definite
diagnosis” was reported in an article by Ghadir and
colleagues on 2020-04-06 [61]. On 2020-07-30, clin-
ical and virologic characteristics of the first seven
cases of COVID-19 in Iran were reported by Yavarian
and colleagues, academics from Tehran University of
Medical Sciences and officials from Iran MOHME
[62]. Numbers and dates of cases and deaths do not
match with correspondent numbers and dates of cases
and deaths officially announced by MOHME. Date of
symptoms onset and date of encounter for the first
patient reported by Ghadir [61] and by Yavarian [62]
do not match.
Fig. 3 Reported and median-scenario estimated daily deaths of COVID-19 in Iran. (1) Mashayekhi S2: Medium scenario, not serious distancing;
People reduce their social [physical] contacts only to 20% of regular level, voluntarily, after number of cases and deaths have increased, and other
settings are like scenario 1 [28]. (2) Deaths CF 5: Reported deaths with a Correction Factor of 5, after Dr. Rick Brennan, Director of Emergency
Operations, World Health Organization [57]. (3) Deaths CF 10: Reported deaths with a Correction Factor of 10, after Russell [58]. (4) MOHME
reported: Official reported deaths via [4, 5]
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A study on all-cause excess mortality and COVID-19-
related deaths in Iran found a correction factor of two
for reported COVID-19 deaths in Iran [63]. Deputy Min-
ister of Health in Iran announced on 2020-10-14 that
the real numbers of COVID-19 deaths In Iran are on
average about two times higher than the official reports
(ranging 1.7 from 2.2 depending on the province), be-
cause they follow the WHO protocols that requires posi-
tive PCR test result [64]. World Health Organization
maintains that’ “Countries have varying approaches to
COVID-19 case definitions. Consequently, the numer-
ator and the denominator of any formula used to calcu-
late fatality rate will vary according to how they are
defined. WHO recommends using the surveillance case
definitions which are available in the WHO interim
guidance on Global surveillance for COVID-19. A
COVID-19 death is defined for surveillance purposes as
a death resulting from a clinically compatible illness in a
probable or confirmed COVID-19 case, unless there is a
clear alternative cause of death that cannot be related to
COVID-19 disease (e.g. trauma). There should be no
period of complete recovery between the illness and
death.” [65]. Moreover, WHO’s “International Guidelines
for Certification and Classification (Coding) of Covid-19
as Cause of Death” maintains the immediately-above-
mentioned for a “COVID-19 death”, and also provide
the following codes. “U07.1 COVID-19, virus identified”
for when the virus was identified, and “U07.2 COVID-
19, virus not identified. Clinically-epidemiologically diag-
nosed COVID-19. Probable COVID-19. Suspected
COVID-19” for when the virus was NOT identified [66].
However, WHO maintains in its “COVID-19 Weekly
Epidemiological Update” of 25 October 2020, that “Data
presented are based on official laboratory-confirmed
Fig. 4 Reported and current (median) scenario cumulative deaths of COVID-19 in Iran, last 4 months of year 2020 and January 2021, International
studies. (1) DELPHI: DELPHI (Differential Equations Leads to Predictions of Hospitalizations and Infections) Epidemiological Case Predictions. Mean
estimate [10]. (2) IHME: Institute for Health Metrics and Evaluation (IHME) Mean estimate [12]. (3) Imperial: Imperial College COVID-19 LMIC
Reports. Mean estimate [13]. (4) LANL: Los Alamos National Laboratory (LANL) COVID-19 Cases and Deaths Forecasts. Mean estimate [14]. (5)
Srivastava: ReCOVER- Accurate Predictions and Resource Management for COVID-19 Epidemic Response. Mean estimate [15]. (6) YYG
(Youyang Gu): COVID-19 Projections Using Machine Learning. Mean estimate [17]. (7) MOHME reported: Ministry of Health and Medical
Education, Iran via [4, 5]
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COVID-19 case and deaths reported to WHO by coun-
try/territories/areas, largely based upon WHO case defi-
nitions and surveillance guidance.” and “A small number
of countries/territories/areas report combined probable
and laboratory-confirmed cases; efforts are underway to
identify these for notation in the data table. Differences
are to be expected between information products pub-
lished by WHO, national public health authorities, and
other sources.” [67].
Another deputy Minister of Health in Iran announced
on 2020-10-18 that the real numbers of COVID-19
deaths and cases of COVID-19 In Iran are on average
about 2.5 times more than the official reports because
the diagnostic test kits have only 30 to 50% ability to
diagnose the disease [68]. A member of High Council of
Iranian Medial Council mentioned on 2020-10-25 that
the real number of COVID-19 deaths is 3–4 times more
than the official reports due to low number of PCR test-
ing [69]. Euro-news quoted Dr. Michael Ryan of WHO
on 2020-10-05, “Around 10% of the world’s population
may have had COVID-19” on about 2020-10-05 [70].
There were 37,738,990 reported global cumulative cases
on 2020-10-05 [49], and 10% of 7.8 billion global popu-
lation is 780 million, and hence the correction factor for
going from reported cases to the total cases is 20.67 at
the global level. If the global average Infection Fatality
Rate (IFR) is about 0.5% (0.2–1.0%) [71–74], then with
780 million expected global cumulative deaths on 2020-
10-05, the expected deaths could be 3,900,000 (1,560,
000-7,800,000). With 1,054,089 reported global cumula-
tive deaths on 2020-10-05, the correction factor for
deaths would be about 3.70 (1.48–7.40) at the global
level. Therefore, at the global average level, the correc-
tion factor for cases is about 20.67, and correction factor
for deaths is about 3.70 (1.48–7.40). Deputy Minister of
Health in Iran announced on 2020-10-25 [75] that based
on a national seroprevalence study, 30 million people
were infected at about the end of Hijri month 2 (about
2020-05-20). If the global average Infection Fatality Rate
(IFR) is about 0.5% (0.2–1.0%) [71–74], and applies to
Iran, then 30 million infections translates to 150,000 (60,
000-300,000) deaths. Official report of cumulative deaths
Fig. 5 Current (median) scenario estimated cumulative deaths of COVID-19 in Iran and 20 other countries of North Africa Middle East, IHME.
IHME: Institute for Health Metrics and Evaluation (IHME) Mean estimate. The Reference or ‘Current projection’ scenario assumes social distancing
mandates are re-imposed for 6 weeks whenever daily deaths reach 8 per million (0.8 per 100,000) [12]
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on 2020-05-20 was 7183, and all of these end up in three
possibilities: (1) correction factor of 21 (8–42) for
COVID-19 deaths in Iran, or (2) the IFR in Iran was
0.024% at that time, or (3) that seroprevalence finding
was wrong. While some politicians and researchers may
wish, advocate, or publish for herd immunity – know-
ingly or unknowingly [76–79], research evidence yet de-
scribe why “COVID-19 herd immunity is unethical and
unachievable” [80, 81]. On a rather daily basis, more and
more announcements are being made by authorities and
officials about higher correction factors for COVID-19
deaths and cases in Iran, or unpreparedness of testing
system or hospital infrastructure for combating the epi-
demic; for which continued quotation and referencing
here would not further help anyone.
Undercounting, under-ascertainment, or under-
reporting is a known issue with the number of official
confirmed cases and deaths, almost in all countries. Fac-
tors such as health system capacity for performing tests,
access of people to testing services, on-time availability
of test results, precision of diagnostic or screening tests,
performance of surveillance systems, and transparency
of health systems affect number of cases and deaths in
official reports. In addition to such factors, SARS-CoV-2
itself has characteristics that might aggravate under-
counting. A study on Santa Clara county in the United
States revealed that prevalence, based on testing anti-
bodies to SARS-CoV-2, is 50–85-fold more than the
confirmed cases [82]. This pattern is different from other
viruses of the Coronaviridae family, such as Middle East
Respiratory Syndrome (MERS-CoV), with an estimated
25–50% asymptomatic to mild cases [83]. Some of the
reviewed studies have estimated number of infected
cases without excluding or mentioning asymptomatic
cases. An implicit conclusion is that their numbers
mainly refer to symptomatic cases, similar to the case
mix of their input data. Different approaches have been
used in studies to the issue of undercounting, under-
ascertainment, or under-reporting. (1) Some studies have
accounted for undercounting in their models: DELPHI
[10], Ghaffarzadegan [41], Gu (YYG) [17], Saberi (web
site) [21], Saberi (article) [22], and Srivastava [15]. (2)
Some studies have not used number of confirmed deaths
and / or cases as input data; Haghdoost [27], Mashaye-
khi [28], Rahimi Rise [29], Tuite [46], and Zhuang [47].
(3) In order to conclude that “In emerging epidemics,
CFR indicator must not be used as a basis to judge the
performance of a health system unless that epidemic
condition has been clarified”, Moradi estimated the “ac-
tual number of COVID-19 cases in Iran based on differ-
ent proposed scenarios for Case Fatality Rate [42]. (4)
Other studies did nothing about the issue of under-
counting, with or without mentioning it. To our best un-
derstanding, the most important issue that can drive the
prediction models’ results misleading and misinforming
is ignoring the issue of undercounting, under-
ascertainment, and under-reporting. Role of the symp-
tomatic cases in spread of the disease was accounted for
only in some studies; DELPHI [10], Ghaffarzadegan [41],
Gu (YYG) [17], Mashayekhi [28], Saberi (article) [22],
Rahimi Rise [29], Srivastava [15].
Some studies provided some sort of subnational esti-
mates as well as national; Haghdoost [27], Moghadami
[36], Muniz-Rodriguez [37], Pourghasemi (PLoS ONE)
[38], Pourghasemi (IJID) [39], and Zhan [40]. Access to
COVID-19 data at provincial and subnational level has
obviously been an important limitation for most re-
searchers. This threatens the usability of models. Natur-
ally, all the provinces are not at the same stage of
epidemic growth, they have different conditions that
affect disease transmission and their capacities to re-
spond to the epidemic are different. This means that
centralized strategies for estimation of the epidemic ex-
tent and intervention options might not fit all the needs
of the subnational levels. Spatial heterogeneity in propa-
gation of epidemics should be taken into account [84].
MOHME has a subnational level defined between the
national and the provincial levels; some of the studies or
operational plans have used these conglomerates of
provinces in Iran, labeled as “climes”, which share rela-
tively homogenous epidemiologic profiles within the
climes before the COVID-19 era. Such conglomerates of
provinces in Iran, or newly designed conglomerates,
might be considered usable in estimation of the epi-
demic propagation in Iran with a smaller number of sub-
national geographic units (i.e. climes), compared to
studying all the provinces, which is more resource-
intensive. Alternatively, there are potential modeling
approaches for simultaneous modeling of different
subnational levels accounting for different stages of
epidemic progression, both with and without access to
detailed province data; for instance, Rojas [85] and
Xiong [86].
The international studies, i.e. DELPHI [10], Gu (YYG)
[17], IHME [12], Imperial [13], LANL [14], and Srivas-
tava [15], generally provide updated estimates on a peri-
odical basis, mostly weekly. This means that all
estimations (from the start date of the epidemic) change
in each version of running model. The usual explanation
for this approach is to feed model with more input data
that can improve prediction and provide an opportunity
for improving methods as well.
Among the models that have used number of con-
firmed cases or deaths as input, only two studies, Ghaf-
farzadegan [41] and Saberi (article) [22], have considered
delayed diagnosis in their calculations; this might be
quite important. The Wuhan municipal headquarters for
COVID-19 epidemic prevention and control released a
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notification and revised the total number of fatalities up
by around 50% to 3869 after reviewing all available
sources of data [87]. There not an unusual practice in
many of death registries that physicians use more gen-
eral terms as the final diagnosis or cause of death when
they cannot or do not have time to match patients’ char-
acteristics with exact definitions. It is more common in
situations like epidemics that all health care workers are
overwhelmed with number of patients and preoccupied
with treating patients. Also, field hospitals and COVID-
19 specific hospices might not be linked properly to
health information systems to share data. Some cases
that were initially classified under more general terms
(such as pneumonia or acute respiratory syndrome) or
even more specified but incorrect diagnoses (such as
seasonal flu) might be re-classified to COVID-19 after
reviewing all clinical data, test results, or autopsies. Five
studies (Ayyoubzadeh [52], Ghaffarzadegan [41], Hagh-
doost [27], Mashayekhi [28], Rahimi Rise [29]) fore-
casted more than one peak for the epidemic.
International studies generally ‘back-cast’ (replicate or
imitate) the officially reported epidemic curves up to the
time where reported data is available, and ‘forecast’ the
epidemic curve under different scenarios for the future.
Prediction of time and magnitude of future waves of the
epidemic is an important aspects of modeling studies.
Also, there is an implicit assumption in all studies or
models, that the socio-economic response capacity will
remain constant over the timespan of the epidemic and
the calendar time period for which estimations are per-
formed; this is not necessarily correct.
As some of the studies have not mentioned enough
details on their epidemic model and statistical methods,
the largest gap was related to not mentioning the
methods used to assess model validity, accuracy, or fit-
ness, and the findings of these methods. Eleven studies
did not report any method used to verify model validity.
Absence of reporting uncertainty intervals for model
output was another downside in statistical methods.
Poor reporting has been one of the common issues in
many of the COVID-19 prediction and estimation stud-
ies [7]. Although guidelines such as TRIPOD are not
specifically designed for this type of studies but can be
used as a base to remind researchers about the standards
of reporting [9]. There have been a few systematic re-
views on COVID-19 epidemiological studies. None of
the studies included in this research were among the in-
cluded studies in Park’s systematic review [88].
Eight studies (DELPHI [10], Ghaffarzadegan [41],
Haghdoost [27], Hsiang [45], Imperial [13], Mashayekhi
[28], Rahimi Rise [29], Thu [48]) have considered sce-
narios to assess the effects of social distancing policies;
this increases the usability of these models, however so-
cial distancing policies have a wide range of methods
and effectiveness. They need to be clarified with more
details in scenarios to increase practical usability of
models for decision making. We expect to see postpone-
ment in the first peak date or reduction of its height (i.e.
flattening the curve) in scenarios based on appropriate
interventions [35]. Most of the studies have ignored
availability and numbers of performed tests to detect
COVID-19 cases; such data were not publicly available
in the first few weeks after start of the epidemic in Iran.
Only two studies (Ghaffarzadegan [41], IHME [12]) in-
cluded test coverage in their model. Evidence on poten-
tial seasonality effects is not conclusive yet, but it has
been proposed by some researchers [36, 37]. This factor
has been considered in three of the models; Ghaffarzade-
gan [41], Haghdoost [27], and IHME [12]. Among the 84
study-model/scenarios, the median scenario of Hagh-
doost [27] was the best model that perfectly forecasted
the cumulative deaths officially reported by MOHME
(Fig. 1).
Non-COVID causes of mortality and morbidity are
also important in epidemic modeling and intervention
planning. Increase in non-COVID all-cause mortality
and morbidity is a tandem phenomenon running along-
side the COVID epidemic, that goes on with less drawn
attention compared to the epidemic. European mortality
monitoring (EuroMOMO) Network has assessed excess
all-cause mortality overall for the participating European
countries and estimated a marked increase [38]. As the
cold season will come, taking into account the influenza
season in estimations, and in particular regarding the
caseload burden to be imposed on the health care sys-
tem. Some COVID cases or deaths might be misclassi-
fied as non-COVID Acute Respiratory Distress
Syndrome (ARDS), influenza, or pneumonia, and ana-
lyses of expected levels of such cases deaths could illu-
minate and improve COVID estimates. Some countries
have expedited release of reports of provisional counts
of death and excess deaths in January to March 2019
and January to March 2020, e.g. Iran [39]. Excess deaths
in provinces of Iran have been assessed in non-peer-
reviewed report [40].
Models differ in their mathematical configuration, desig-
nated start date of the epidemic for a given population,
use of parameter values as input (e.g. Basic reproduction
number, R0; or Case Fatality Ratio, CFR), use of data with
varying time lengths to calibrate the model, and interven-
tions formulated in scenarios. As Panovska-Griffiths
explains, the ultimate questions of “can mathematical
modelling solve the current Covid-19 crisis” or “which
model is correct” evolve to realization that “no one model
can give all the answers” and that “we need more models
that answer complementary subquestions that can piece
together the jigsaw and halt COVID- 19 spread” [41]. Esti-
mation and use of a single correction factor for both the
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cases and deaths all across the time for any given country
assumes invariance of diagnosis, detection and reporting
completeness for infections and mortality during the epi-
demic; which is not necessarily true.
We believe that increasing public access to data on
number of confirmed or suspected cases (and their out-
comes of death and recovery), healthcare utilization by
patients with COVID-19 (such as hospital admission, in-
tensive care utilization and performed tests) both at na-
tional and province levels may improve accuracy and
usability of models, and eventually lead to prevention of
more cases and deaths. Estimates of cumulative deaths
are less dependent on testing compared to cumulative
cases. Estimates of daily deaths and daily cases look
at possible waves and peak heights. Estimation of all
these four outcomes can depict a better trajectory
and extent of the epidemic. We suggest researcher to
consider subnational estimations, as well as factors
such as non-pharmacological interventions, test avail-
ability, age-stratification, and delayed diagnosis for
updating their models. Some of the reports do not
have enough details on methods and results that re-
duces their usage in disease control. We recommend
researchers to consider standard items for reporting
their models to increase practical use of the findings.
It would also be vitally desirable if the veteran and
current researchers of epidemic modeling could de-
velop a consensus-based declaration on Preferred
Reporting Items of Epidemic Modeling Studies, pref-
erably before the next pandemic.
The results of epidemic modeling studies are certainly
uncertain. The way in which the problem of uncertainty
is handled by some of the national-level and inter-
national models of COVID-19 epidemic has been criti-
cized in Davey Smith’s ‘Covid-19’s known unknowns’
[89], albeit without suggestion of any solutions beyond
“respecting uncertainty”. Beyond the considerations of
usability and certainty of epidemic models, the immense
problem for people on the ground who suffer from the
direct and indirect mortality, morbidity, and economic
hardship from COVID-19, is the actually materialized
accountability and the public health and economic inter-
ventions the governments have undertaken, are doing,
and will perform – with or without the best or worst es-
timation models’ results. As demonstrated in Fig. 5, Iran
would have the highest estimated death toll among the
21 countries in in North Africa Middle East region, with
78,693 estimated cumulative deaths under the current
scenario on 2021-02-01, that is about 3.5 times more
than the second highest death toll of 22,614 in Iraq [12].
Model estimates predict an ominous course of epidemic
progress in Iran. Wisdom, political and economic com-
mitment, and effective policy making, and management
are needed indeed.
Study limitations
We did not search international databases other than
PubMed, did not describe subnational results, and did
not assess other outcomes such as utilization of intensive
care unit (ICU) beds. We did not have access to the full
report of one of the studies (Mashayekhi [28]). In the
abridged study report we found, we noticed some dis-
crepancies in outcome prediction values in different
graphs [26]. None of our digitized outcome predictions
reported here are 100% accurate. All of them are wrong
in terms of having non-prefect accuracy. However, the
error range is mostly around 1 or 2% points and below
5% for almost all instances.
Conclusions
We believe that COVID-19 models which consider
scenarios for policy options, include key influencing
factors such as role of asymptomatic cases in spread
of the disease, under-reporting of deaths and cases,
testing availability, and delayed diagnosis, and provide
estimates for subnational regions are more useful for
epidemic control. Not accounting for under-reporting
drives the models’ results misleading. Increasing pub-
lic access to COVID-19 related data is very important
for improving quality of models and enhancing
evidence-informed decisions to prevent more deaths.
To increase the usability of reports, researchers
should consider requirements of reporting a predic-
tion or estimation model.
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